Tenders Are Invited For Pharmaceutical Products – Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130A Paragraph 8 Sgb V For Pharmaceuticals (Open House Procedure)

Pharmaceutical Products – Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130A Paragraph 8 Sgb V For Pharmaceuticals (Open House Procedure). The Procurement Requirement Includes All Medicinal Products With The Active Ingredients Named In Appendix 3 To The Conditions Of Participation (So-Called List Of Active Ingredients And Deadlines). The Procurement Requirements Were Not Divided Into Lots. This Is An Open House Procedure. To The Extent That Wording Is Used In This Announcement That Indicates The Division Of Procurement Requirements Into One Or More Lots, This Is Solely Due To The Specifications Of This Announcement Form. In This Context, Reference Is Made To The Non-Applicability Of Procurement Regulations Described At The Beginning Of Section 2.1. The Aok Starts The Open House Process With The Following Active Ingredients (So-Called Starting Active Ingredients): 1. Aripiprazole* (Serial No. 1 Of Appendix 3 To The Conditions Of Participation); 2. Glatiramer Acetate (Section No. 2 Of Appendix 3 To The Conditions Of Participation); 3. Peginterferon Beta-1A (Section No. 3 Of Appendix 3 To The Conditions Of Participation); 4. Somatropin (Section No. 4 Of Appendix 3 To The Conditions Of Participation); 5. Ustekinumab (Section No. 5 Of Appendix 3 To The Conditions Of Participation). *For Medicines With The Active Ingredient Aripiprazole, Only Medicines With This Active Ingredient In The Sustained-Release Dosage Forms With The Atc Code N05ax12 Are Required For Procurement. The Aok Reserves The Right To Expand The Procurement Requirements Of This Open House Procedure As The Procedure Progresses, I.E. H. Appendix 3 To The Conditions Of Participation Should Be Supplemented With Additional Active Ingredients. This Means That Discount Agreements For Medicines With These Other Active Ingredients Would Also Be Subject To The Present Open House Procedure. Of Course, This Would Not Expand The Content Of Contracts Already Concluded For Other Active Ingredients, But Rather A New Contract Would Have To Be Concluded For Each Active Ingredient (See Also Sections A.I.1, A.I.4 And A.Iii.4 Of The Conditions Of Participation). If The Aok Decides To Expand The Procurement Requirements, It Will Announce This Fact In A Further Contract Announcement (So-Called Follow-Up Announcement), Which Refers To This Contract Announcement (So-Called Initial Announcement), In The Supplement To The Official Journal Of The European Union. Further Information On A Possible Expansion Of Procurement Requirements Is Contained In The Conditions Of Participation (Section A.I.4). Contracts For Medicines With The Starting Active Ingredients Will Not Be Concluded Until July 1, 2024 At The Earliest. All Discount Agreements Concluded As Part Of This Open House Procedure End On December 31, 2026. The Active Ingredient Ustekinumab (Term Ends December 31, 2024) And The Active Ingredient Combination Beclometasone Dipropionate + Formoterol Hemifumarate-1-Water + Glycopyrronium Bromide (Term Ends March 31, 2025) Are Excluded. For The Active Ingredients Somatropin, Indacaterol Maleate + Glycopyrronium Bromide And Tacrolimus-1 Water, The Open House Procedure Will Not Be Continued Beyond June 30, 2026. The Contract Term Is Limited And